L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 51322-75-9 REGISTRY
ED Entered STN: 16 Nov 1984
CN 2,1,3-Benzothiadiazol-4-amine, 5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-
(9CI) (CA INDEX NAME)
OTHER NAMES:
CN Tizanidine
MF C9 H8 Cl N5 S
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN*, BIOSIS,
BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU,
DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IMSDRUGNEWS,
IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PHAR, PROMT, PROUSDDR, PS,
RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

258 REFERENCES IN FILE CA (1907 TO DATE)
7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
258 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 181695-72-7 REGISTRY
ED Entered STN: 10 Oct 1996
CN Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 4-(5-Methyl-3-phenylisoxazol-4-yl)benzenesulfonamide
CN Bextra
CN SC 65872
CN Valdecoxib
CN Valecoxib
MF C16 H14 N2 O3 S
CI COM
SR CA
LC STN Files: ADISINSIGHT, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CSCHEM, EMBASE, HSDB*, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MRCK*, PATDPASPC, PHAR, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

599 REFERENCES IN FILE CA (1907 TO DATE)
26 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
604 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

```
=> E "TIZANIDINE"/CN 25
E1            1     TIZ 80/2/CN
E2            1     TIZABRIN/CN
E3            1 --> TIZANIDINE/CN
E4            1     TIZANIDINE HYDROCHLORIDE/CN
E5            1     TIZANIDINE-IBUPROFEN MIXT./CN
E6            1     TIZANOX/CN
E7            1     TIZATE B/CN
E8            1     TIZIAN RED/CN
E9            1     TIZIDE/CN
E10           1     TIZINE/CN
E11           1     TIZOLE/CN
E12           1     TIZOLEMIDE/CN
E13           1     TIZON/CN
E14           1     TIZOPROLIC ACID/CN
E15           1     TIZOXANIDE/CN
E16           1     TIZOXANIDE GLUCURONIDE/CN
E17           1     TIZRYAL-1/CN
E18           1     TIZRYAL-2/CN
E19           2     TJ/CN
E20           1     TJ (ACRYLIC POLYMER)/CN
E21           1     TJ (COMPLEXING AGENT)/CN
E22           1     TJ 04CN/CN
E23           1     TJ 05/CN
E24           1     TJ 066/CN
E25           1     TJ 1/CN

=> S E3
L1            1 TIZANIDINE/CN

=> DIS L1 1 IDE
THE ESTIMATED COST FOR THIS REQUEST IS 1.90 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2006 ACS on STN
RN   51322-75-9  REGISTRY
ED   Entered STN:  16 Nov 1984
CN   2,1,3-Benzothiadiazol-4-amine, 5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-
     (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   Tizanidine
MF   C9 H8 Cl N5 S
CI   COM
LC   STN Files:   ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN*, BIOSIS,
       BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU,
       DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IMSDRUGNEWS,
       IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PHAR, PROMT, PROUSDDR, PS,
       RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
         (*File contains numerically searchable property data)
     Other Sources:   WHO
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

258 REFERENCES IN FILE CA (1907 TO DATE)
7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
258 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> E "TIZANIDINE"/CN 25
E1            1      TIZ 80/2/CN
E2            1      TIZABRIN/CN
E3            1 --> TIZANIDINE/CN
E4            1      TIZANIDINE HYDROCHLORIDE/CN
E5            1      TIZANIDINE-IBUPROFEN MIXT./CN
E6            1      TIZANOX/CN
E7            1      TIZATE B/CN
E8            1      TIZIAN RED/CN
E9            1      TIZIDE/CN
E10           1      TIZINE/CN
E11           1      TIZOLE/CN
E12           1      TIZOLEMIDE/CN
E13           1      TIZON/CN
E14           1      TIZOPROLIC ACID/CN
E15           1      TIZOXANIDE/CN
E16           1      TIZOXANIDE GLUCURONIDE/CN
E17           1      TIZRYAL-1/CN
E18           1      TIZRYAL-2/CN
E19           2      TJ/CN
E20           1      TJ (ACRYLIC POLYMER)/CN
E21           1      TJ (COMPLEXING AGENT)/CN
E22           1      TJ 04CN/CN
E23           1      TJ 05/CN
E24           1      TJ 066/CN
E25           1      TJ 1/CN

=> E "VALDECOXIB"/CN 25
E1            1      VALCYTE/CN
E2            1      VALDAMAR/CN
E3            1 --> VALDECOXIB/CN
E4            1      VALDECOXIB POTASSIUM/CN
E5            1      VALDECOXIB SODIUM/CN
E6            1      VALDET 4016/CN
E7            1      VALDET 79N/CN
E8            1      VALDETAMIDE/CN
E9            1      VALDIATE/CN
E10           1      VALDIBERINE/CN
E11           1      VALDIBERINE DIACETATE/CN
E12           1      VALDICE/CN
E13           1      VALDIPROMIDE/CN
E14           1      VALDISOVAL/CN
E15           1      VALDISPERT/CN
E16           1      VALDIVIANINE/CN
```

```
E17          1     VALDIVIANINE ACETATE/CN
E18          1     VALDIVIN/CN
E19          1     VALDIVIN, DIHYDRATE/CN
E20          1     VALDIVIOLIDE/CN
E21          1     VALDIVIONE/CN
E22          1     VALDIVONE A/CN
E23          1     VALDIVONE B/CN
E24          1     VALEANS/CN
E25          1     VALECHLORIN/CN

=> S E3
L2           1 VALDECOXIB/CN

=> DIS L2 1 IDE
THE ESTIMATED COST FOR THIS REQUEST IS 1.90 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L2   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2006 ACS on STN
RN   181695-72-7  REGISTRY
ED   Entered STN:  10 Oct 1996
CN   Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)- (9CI)  (CA INDEX
     NAME)
OTHER NAMES:
CN   4-(5-Methyl-3-phenylisoxazol-4-yl)benzenesulfonamide
CN   Bextra
CN   SC 65872
CN   Valdecoxib
CN   Valecoxib
MF   C16 H14 N2 O3 S
CI   COM
SR   CA
LC   STN Files:   ADISINSIGHT, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS,
       CASREACT, CBNB, CHEMCATS, CSCHEM, EMBASE, HSDB*, IMSDRUGNEWS,
       IMSPATENTS, IMSRESEARCH, IPA, MRCK*, PATDPASPC, PHAR, PROUSDDR, PS,
       RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
         (*File contains numerically searchable property data)
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

             599 REFERENCES IN FILE CA (1907 TO DATE)
              26 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
             604 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
```

```
                                                    ENTRY    SESSION
FULL ESTIMATED COST                                 14.64      14.85

FILE 'CAPLUS' ENTERED AT 09:45:07 ON 11 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 11 Oct 2006  VOL 145 ISS 16
FILE LAST UPDATED: 9 Oct 2006  (20061009/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s 181695-72-7
   REG1stRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L4          604 L3

=> s 51322-75-9
   REG1stRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L6          258 L5

=> s l4 and l6
L7            5 L4 AND L6

=> d ti au abs so py 1-5

L7   ANSWER 1 OF 5  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Pharmaceutical compositions comprising an agent with serotonin receptor
     modulating activity for sleep disorders
IN   Rariy, Roman V.; Heffernan, Michael
```

AB Pharmaceutical compns. are provided for the pharmacol. treatment of breathing disorders and, more specifically, to compns. containing agents having serotonin receptor modulating activity for the alleviation of sleep apnea (central and obstructive) and other sleep-related breathing disorders wherein the active ingredients are released such as to extend effective blood plasma concns. across the period of sleep. For example, ondansetron immediate release tablets were prepared containing ondansetron HCl dihydrate 9.98 mg, lactose 29.14 mg, Prosolv 50 29.14 mg, Ac-Di-Sol 3.75 mg, SDS 1.5 mg, Aerosil 0.75 mg, and Mg stearate 0.75 mg. Ondansetron immediate release tablets were then coated with Eudragit L100/S100 blend to obtain delayed release tablets.

SO PCT Int. Appl., 57 pp.
CODEN: PIXXD2

PY 2006

L7 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

TI Simultaneous estimation of valdecoxib and tizanidine by Vierodt's and Q-analysis UV spectrophotometric method

AU Nagulwar, Vaishali; Tajne, M. R.; Upadhaye, Kanchan; Bakhle, Suparna; Deshpande, Shilpa; Wadetwar, Rita

AB The simple, accurate and precise Vierodt's and Q-anal. UV Spectrophotometric method was developed for the simultaneous determination of valdecoxib and tizanidine in combined tablet dosage form. Shimadzu UV-1601 instrument was used and the λmax of valdecoxib and tizanidine was found to be 237 nm and 319 nm, resp. In Q-anal., the isoabsorptive point for both the drugs was found at 289.5 nm. The linearity range lies between 5-30 μg/mL for valdecoxib and 0.5-3 μg/mL for tizanidine at their resp. wavelengths.

SO Indian Journal of Pharmaceutical Sciences (2005), 67(5), 624-627
CODEN: IJSIDW; ISSN: 0250-474X

PY 2005

L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

TI Pharmaceutical formulation containing muscle relaxant and cox-ii inhibitor

IN Sen, Nilendu; Chandurkar, Kavita; Krishnan, Anandi

AB Disclosed is an extended release pharmaceutical formulation comprising a muscle relaxant drug, such as tizanidine, in combination with a cyclooxygenase-2 inhibitor, such as valdecoxib. The formulations are useful in the treatment and management of painful inflammatory conditions associated with, for example, skeletal muscle spasms. For example, capsules containing tizanidine 6 mg extended release formulation and valdecoxib 20 mg immediate release formulation have good drug bioavailability.

SO U.S. Pat. Appl. Publ., 14 pp.
CODEN: USXXCO

PY 2005
2005

L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

TI Stereoisomers of p-hydroxy-milnacipran, and therapeutic use

IN Rariy, Roman V.; Heffernan, Michael; Buchwald, Stephen L.; Swager, Timothy M.

AB The invention relates generally to the enantiomers of p-hydroxymilnacipran or congeners thereof. Biol. assays revealed that racemic p-hydroxymilnacipran is approx. equipotent in inhibiting serotonin and norepinephrine uptake (IC50 = 28.6 nM for norepinephrine, IC50 = 21.7 nM for serotonin). Interestingly, (+)-p-hydroxymilnacipran is a more potent inhibitor of norepinephrine uptake than serotonin uptake (IC50 = 10.3 nM for norepinephrine, IC50 = 22 nM for serotonin). In contrast, (-)-p-hydroxymilnacipran is a more potent inhibitor of serotonin uptake compared to norepinephrine uptake (IC50 = 88.5 nM for norepinephrine, IC50 = 40.3 nM for serotonin). The invention also relates to salts and prodrug forms of the above compds. In certain embodiments, the compds. of the invention and a pharmaceutically acceptable excipient are combined to prepare a formulation for administration to a patient. Finally,the

```
     invention relates to methods of treating mammals suffering from various
     afflictions, e.g., depression, chronic pain, or fibromyalgia, comprising
     administering to a mammal in need thereof a therapeutically effective amount
     of a compound of the invention.  Compound preparation is included.
SO   PCT Int. Appl., 163 pp.
     CODEN: PIXXD2
PY   2004
     2004
     2004
     2004
     2004
     2006
     2005
     2006

L7   ANSWER 5 OF 5  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Novel pharmaceuticals comprising drug conjugates with polypeptide carriers
IN   Picariello, Thomas
AB   A pharmaceutical composition comprising a polypeptide and an active agent
     attached to said polypeptide is disclosed.
SO   PCT Int. Appl., 2059 pp.
     CODEN: PIXXD2
PY   2003
     2003
     2003
     2003
     2006
     2004
     2006


=> s controlled(w)release or capsule or tablet or extended(w)release
        534697 CONTROLLED
             1 CONTROLLEDS
        534697 CONTROLLED
                 (CONTROLLED OR CONTROLLEDS)
        475342 RELEASE
         23823 RELEASES
        489594 RELEASE
                 (RELEASE OR RELEASES)
         20580 CONTROLLED(W)RELEASE
         38410 CAPSULE
         41037 CAPSULES
         63622 CAPSULE
                 (CAPSULE OR CAPSULES)
         45085 TABLET
         69928 TABLETS
         81195 TABLET
                 (TABLET OR TABLETS)
        245029 EXTENDED
             3 EXTENDEDS
        245032 EXTENDED
                 (EXTENDED OR EXTENDEDS)
        475342 RELEASE
         23823 RELEASES
        489594 RELEASE
                 (RELEASE OR RELEASES)
          1535 EXTENDED(W)RELEASE
L8      145812 CONTROLLED(W)RELEASE OR CAPSULE OR TABLET OR EXTENDED(W)RELEASE

=> s l4 and l6 and l8
L9            4 L4 AND L6 AND L8

=> dup rem
```

ENTER L# LIST OR (END):19
PROCESSING COMPLETED FOR L9
L10 4 DUP REM L9 (0 DUPLICATES REMOVED)
ANSWERS '1-4' FROM FILE CAPLUS

=> d ti au abs so py 1-4

L10 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
TI Pharmaceutical compositions comprising an agent with serotonin receptor modulating activity for sleep disorders
IN Rariy, Roman V.; Heffernan, Michael
AB Pharmaceutical compns. are provided for the pharmacol. treatment of breathing disorders and, more specifically, to compns. containing agents having serotonin receptor modulating activity for the alleviation of sleep apnea (central and obstructive) and other sleep-related breathing disorders wherein the active ingredients are released such as to extend effective blood plasma concns. across the period of sleep. For example, ondansetron immediate release tablets were prepared containing ondansetron HCl dihydrate 9.98 mg, lactose 29.14 mg, Prosolv 50 29.14 mg, Ac-Di-Sol 3.75 mg, SDS 1.5 mg, Aerosil 0.75 mg, and Mg stearate 0.75 mg. Ondansetron immediate release tablets were then coated with Eudragit L100/S100 blend to obtain delayed release tablets.
SO PCT Int. Appl., 57 pp.
CODEN: PIXXD2
PY 2006

L10 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
TI Pharmaceutical formulation containing muscle relaxant and cox-ii inhibitor
IN Sen, Nilendu; Chandurkar, Kavita; Krishnan, Anandi
AB Disclosed is an extended release pharmaceutical formulation comprising a muscle relaxant drug, such as tizanidine, in combination with a cyclooxygenase-2 inhibitor, such as valdecoxib. The formulations are useful in the treatment and management of painful inflammatory conditions associated with, for example, skeletal muscle spasms. For example, capsules containing tizanidine 6 mg extended release formulation and valdecoxib 20 mg immediate release formulation have good drug bioavailability.
SO U.S. Pat. Appl. Publ., 14 pp.
CODEN: USXXCO
PY 2005
2005

L10 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
TI Simultaneous estimation of valdecoxib and tizanidine by Vierodt's and Q-analysis UV spectrophotometric method
AU Nagulwar, Vaishali; Tajne, M. R.; Upadhaye, Kanchan; Bakhle, Suparna; Deshpande, Shilpa; Wadetwar, Rita
AB The simple, accurate and precise Vierodt's and Q-anal. UV Spectrophotometric method was developed for the simultaneous determination of valdecoxib and tizanidine in combined tablet dosage form. Shimadzu UV-1601 instrument was used and the λmax of valdecoxib and tizanidine was found to be 237 nm and 319 nm, resp. In Q-anal., the isoabsorptive point for both the drugs was found at 289.5 nm. The linearity range lies between 5-30 μg/mL for valdecoxib and 0.5-3 μg/mL for tizanidine at their resp. wavelengths.
SO Indian Journal of Pharmaceutical Sciences (2005), 67(5), 624-627
CODEN: IJSIDW; ISSN: 0250-474X
PY 2005

L10 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
TI Novel pharmaceuticals comprising drug conjugates with polypeptide carriers
IN Picariello, Thomas
AB A pharmaceutical composition comprising a polypeptide and an active agent attached to said polypeptide is disclosed.

SO PCT Int. Appl., 2059 pp.
CODEN: PIXXD2
PY 2003
2003
2003
2003
2006
2004
2006

=>